P
Peter S. Nelson
Researcher at Fred Hutchinson Cancer Research Center
Publications - 497
Citations - 57568
Peter S. Nelson is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 96, co-authored 425 publications receiving 47923 citations. Previous affiliations of Peter S. Nelson include University of Washington & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer.
Elahe A. Mostaghel,Stephanie T. Page,Daniel W. Lin,Ladan Fazli,Ilsa Coleman,Lawrence D. True,Beatrice S. Knudsen,David L. Hess,Colleen C. Nelson,Alvin M. Matsumoto,William J. Bremner,Martin E. Gleave,Peter S. Nelson,Peter S. Nelson +13 more
TL;DR: Optimal clinical efficacy will require testing of novel approaches targeting complete suppression of systemic and intracrine contributions to the prostatic androgen microenvironment.
Journal ArticleDOI
The program of androgen-responsive genes in neoplastic prostate epithelium
Peter S. Nelson,Nigel J. Clegg,Hugh Arnold,Camari Ferguson,Michael Bonham,James F. White,Leroy Hood,Biaoyang Lin +7 more
TL;DR: The results identify previously uncharacterized and unsuspected genes whose expression levels are directly or indirectly regulated by androgens and provide a comprehensive temporal view of the transcriptional program of human androgen-responsive cells.
Journal ArticleDOI
Addressing overdiagnosis and overtreatment in cancer: a prescription for change
Laura J. Esserman,Ian M. Thompson,Brian J. Reid,Peter S. Nelson,David F. Ransohoff,H. Gilbert Welch,Shelley Hwang,Donald A. Berry,Kenneth W. Kinzler,William C. Black,Mina J. Bissell,Howard L. Parnes,Sudhir Srivastava +12 more
TL;DR: Changing the terminology for some of the lesions currently referred to as cancer will allow physicians to shift medicolegal notions and perceived risk to reflect the evolving understanding of biology, be more judicious about when a biopsy should be done, and organise studies and registries that offer less invasive approaches for indolent disease.
Journal ArticleDOI
Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling
Eric G. Bluemn,Eric G. Bluemn,Ilsa Coleman,Jared M. Lucas,Roger Coleman,Susana Hernandez-Lopez,Robin Tharakan,Daniella Bianchi-Frias,Ruth Dumpit,Arja Kaipainen,Alexandra Corella,Yu Chi Yang,Michael D. Nyquist,Elahe A. Mostaghel,Elahe A. Mostaghel,Andrew C. Hsieh,Andrew C. Hsieh,Xiaotun Zhang,Eva Corey,Lisha G. Brown,Holly M. Nguyen,Kenneth J. Pienta,Michael Ittmann,Michael T. Schweizer,Lawrence D. True,David Wise,Paul S. Rennie,Robert L. Vessella,Colm Morrissey,Peter S. Nelson +29 more
TL;DR: Results indicate that FGF/MAPK blockade may be particularly efficacious against mPCs with an AR-null phenotype, and this work is concerned with double-negative PCs, which are notable for elevated FGF and MAPK pathway activity.
Journal ArticleDOI
The Gene Expression Program of Prostate Fibroblast Senescence Modulates Neoplastic Epithelial Cell Proliferation through Paracrine Mechanisms
TL;DR: The concept that aging-related changes in the prostate microenvironment may contribute to the progression of prostate neoplasia is supported.